Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Development of a humanized mouse model with functional human materno-fetal interface immunity
Shuai Dong, … , Yong-Guang Yang, Zheng Hu
Shuai Dong, … , Yong-Guang Yang, Zheng Hu
Published October 22, 2024
Citation Information: JCI Insight. 2024;9(20):e176527. https://doi.org/10.1172/jci.insight.176527.
View: Text | PDF
Research Article Immunology Reproductive biology

Development of a humanized mouse model with functional human materno-fetal interface immunity

  • Text
  • PDF
Abstract

Materno-fetal immunity possesses specialized characteristics to ensure pathogen clearance while maintaining tolerance to the semiallogeneic fetus. Most of our understanding on human materno-fetal immunity is based on conventional rodent models that may not precisely represent human immunological processes owing to the huge evolutionary divergence. Herein, we developed a pregnant human immune system (HIS) mouse model through busulfan preconditioning, which hosts multilineage human immune subset reconstitution at the materno-fetal interface. Human materno-fetal immunity exhibits a tolerogenic feature at the midgestation stage (embryonic day [E] 14.5), and human immune regulatory subsets were detected in the decidua. However, the immune system switches to an inflammatory profile at the late gestation stage (E19). A cell–cell interaction network contributing to the alternations in the human materno-fetal immune atmosphere was revealed based on single-cell RNA-Seq analysis, wherein human macrophages played crucial roles by secreting several immune regulatory mediators. Furthermore, depletion of Treg cells at E2.5 and E5.5 resulted in severe inflammation and fetus rejection. Collectively, these results demonstrate that the pregnant HIS mouse model permits the development of functional human materno-fetal immunity and offers a tool for human materno-fetal immunity investigation to facilitate drug discovery for reproductive disorders.

Authors

Shuai Dong, Cong Fu, Chang Shu, Min Xie, Yan Li, Jun Zou, Yi-Zi Meng, Peng Xu, Yan-Hong Shan, Hui-Min Tian, Jin He, Yong-Guang Yang, Zheng Hu

×

Figure 1

Construction of a pregnant HIS mouse model with high levels of human lymphohematopoietic cell reconstitution.

Options: View larger image (or click on image) Download as PowerPoint
Construction of a pregnant HIS mouse model with high levels of human lym...
(A–C) Ratios (mean ± SEM) of multilineage human lymphohematopoietic cell reconstitution within human CD45+ plus mouse CD45+ cell population of HIS mice made by intravenous injection of human CD34+ fetal liver cells and transplantation of human fetal thymic tissue under the renal capsule after preconditioning by TBI (A; n = 5), limb local irradiation (B; n = 8), or busulfan treatment (C; n = 19). Percentages of human CD45+ leukocytes, CD3+ T cells, CD19+/CD20+ B cells, NK cells, and CD33+ myeloid cells in PBMCs at indicated weeks were shown. An unpaired t test was used to analyze the differences in the ratios of human CD45+ cells, T cells, and B cells in the PBMCs at week 9 between the TBI and busulfan groups: CD45+ cells: P < 0.01; T cells: P < 0.001; B cells: P < 0.0001. (D) The average weight of neonatal mice born to NSG or HIS mice that were mated with BALB/c male mice (busulfan treatment, n = 5). Box plots show the interquartile range, median (line), and minimum and maximum (whiskers). (E) The number of neonatal mice born by NSG or humanized mice that were mated with BALB/c male mice (busulfan treatment, n = 5). (F) The average fetus number (mean ± SEM) of pregnant HIS mice made by mating with NSG males (n = 12) or BALB/c males (n = 13) summarized (busulfan treatment) at E14.5. (G) Ratio of placental junctional to labyrinth zone (JZ/L ratio) in humanized mice (hu-mice) (n = 10) and NSG mice (n = 6) on E14.5. (H) Pictures of placentas and fetuses of a representative HIS mouse euthanized at E14.5 were shown. Statistical analyses were performed using unpaired t test (D–G).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts